glp 1 muscle loss Weighing the risk of GLP-1 treatment in older adults: Should we be concerned about sarcopenic obesity? GLP-1 Drugs & What They

Description

International AEM Malta Edward John Despott UOM Georgios Kalopitas Alberto Murino Fujifilm Healthcare Europe European Society of Gastrointestinal Endoscopy (ESGE) UEG - United European Gastroenterology American Society for Gastrointestinal Endoscopy (ASGE) Endoscopy on Air Foundation for Interventional & Therapeutic Endoscopy Erbe Group American College of Gastroenterology To view or add a comment, sign in Sphenopalatine Ganglion Radiofrequency Ablation for Craniofacial Pain: A Comprehensive Review of Anatomy, Procedural Technique, Clinical Evidence, and Interdisciplinary Implications --- --- Dr Indunil Karunarathna Uva Clinical Research Lab 2026 Uva Clinical Anaesthesia and Intensive Care ISSN 2827-7198, 2026 The sphenopalatine ganglion (SPG) DOI:10.5281/zenodo.20271746 , also known as the pterygopalatine ganglion, is a major extracranial parasympathetic hub with critical roles in trigeminal autonomic cephalalgias (TACs) and other refractory craniofacial pain syndromes

Some primary care providers can also prescribe these medications

India is projected to show the highest regional CAGR at 8.4% during the forecast period, driven by the growing prevalence of diabetes, increasing healthcare access, and expanding awareness about GLP-1 therapies in the region

Regression of MASH showed dose dependency, with the 15 mg dose exhibiting the best response at 62% (vs

Nauck MA, DAlessio DA (2022) Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction